1型糖尿病晚期肾病国际队列研究:终末期肾病与死亡风险差异
研究比较美国Joslin、芬兰FinnDiane、丹麦Steno和法国INSERM四个国际队列中1型糖尿病合并持续大量白蛋白尿且CKD 1-3期患者的ESRD和死亡风险。随访15,685患者年,ESRD发生505例(32/1000患者年),非ESRD死亡228例(14/1000患者年)。调整分析显示ESRD风险Joslin最高(HR 1.44 vs FinnDiane,P=0.003),Steno最低(HR 0.54,P<0.001);非ESRD死亡Joslin最低(HR 0.68,P=0.003)。
要点
- 1型糖尿病晚期肾病患者ESRD和非ESRD死亡风险仍很高,且存在国际差异。
- ESRD风险与男性、年轻、低eGFR、高白蛋白/肌酐比、高HbA1c、高收缩压和吸烟相关。
- 非ESRD死亡风险与年龄较大、吸烟和基线eGFR较高相关。
核心结论
- 尽管几乎普遍接受肾脏保护治疗,1型糖尿病晚期肾病患者进展至ESRD和死亡的风险仍很高,且国家间存在差异。
- 寻找这些差异的原因可能有助于降低这些结局的风险。
研究设计与样本
- 国际多队列研究,纳入1990年代和2000年代初四个队列中CKD 1-3期、持续大量白蛋白尿的白种人1型糖尿病患者。
- 队列包括Joslin Clinic(美国,432例)、FinnDiane(芬兰,486例)、Steno Diabetes Center Copenhagen(丹麦,368例)和INSERM(法国,232例)。
- 随访3-18年,每年测量肌酐以确定ESRD和 non-ESRD 死亡。
主要发现
- 随访15,685患者年,发生505例ESRD(发生率32/1000患者年)和228例非ESRD死亡(发生率14/1000患者年)。
- ESRD风险与男性、较年轻年龄、较低eGFR、较高白蛋白/肌酐比、较高HbA1c、较高收缩压和吸烟相关。
- 非ESRD死亡风险与年龄较大、吸烟和基线eGFR较高相关。
- 调整分析中,ESRD风险Joslin最高(vs FinnDiane HR 1.44,P=0.003),Steno最低(HR 0.54,P<0.001)。
- 非ESRD死亡Joslin最低(vs 其他队列 HR 0.68,P=0.003)。
关键数值与推荐
- ESRD发生率32/1000患者年,非ESRD死亡率14/1000患者年。
- ESRD风险Joslin vs FinnDiane HR 1.44(P=0.003),Steno HR 0.54(P<0.001)。
- 非ESRD死亡Joslin vs 其他队列 HR 0.68(P=0.003)。
临床怎么用
- 对1型糖尿病合并大量白蛋白尿和CKD 1-3期患者,应强化管理可改变危险因素如血糖、血压和吸烟。
- 需关注不同国家间ESRD和死亡风险的差异,探索其原因以改善预后。
局限性
- 研究仅纳入白种人患者,结果可能不适用于其他种族。
- 观察性设计不能确定因果关系。
- 竞争风险未解释国际差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with type 1 diabetes and diabetic nephropathy are targets for intervention to reduce high risk of end-stage renal disease (ESRD) and deaths. This study compares risks of these outcomes in four international cohorts. RESEARCH DESIGN AND METHODS: In the 1990s and early 2000s, Caucasian patients with type 1 diabetes with persistent macroalbuminuria in chronic kidney disease stages 1-3 were identified in the Joslin Clinic (U.S., 432), Finnish Diabetic Nephropathy Study (FinnDiane) (Finland, 486), Steno Diabetes Center Copenhagen (Denmark, 368), and INSERM (France, 232) and were followed for 3-18 years with annual creatinine measurements to ascertain ESRD and deaths unrelated to ESRD. RESULTS: During 15,685 patient-years, 505 ESRD cases (rate 32/1,000 patient-years) and 228 deaths unrelated to ESRD (rate 14/1,000 patient-years) occurred. Risk of ESRD was associated with male sex; younger age; lower estimated glomerular filtration rate (eGFR); higher albumin/creatinine ratio, HbA1c, and systolic blood pressure; and smoking. Risk of death unrelated to ESRD was associated with older age, smoking, and higher baseline eGFR. In adjusted analysis, ESRD risk was highest in Joslin versus reference FinnDiane (hazard ratio [HR] 1.44, P = 0.003) and lowest in Steno (HR 0.54, P < 0.001). Differences in eGFR slopes paralleled risk of ESRD. Mortality unrelated to ESRD was lowest in Joslin (HR 0.68, P = 0.003 vs. the other cohorts). Competing risk did not explain international differences in the outcomes. CONCLUSIONS: Despite almost universal renoprotective treatment, progression to ESRD and mortality in patients with type 1 diabetes with advanced nephropathy are still very high and differ among countries. Finding causes of these differences may help reduce risk of these outcomes.
引用
- Skupien J, Smiles AM, Valo E, et al. Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. Diabetes Care. 2018. PMID: 30455333. doi:10.2337/dc18-1369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。